Latest filing published 12 Jun 2018 for PDL BIOPHARMA, INC., €127k.
Insider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Paul W. Sandman: trading record in brief
Paul W. Sandman discloses dealings in 2 companies, chiefly Boston Scientific Corp and PDL Biopharma, Inc. The record holds 46 filings, for trades running from 14 December 2006 to 8 June 2018.
In open-market terms, that means 2 purchases worth €112k on one side and 26 sales worth €3.7M on the other. Taken together, the sales exceed the purchases by €3.6M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 12 share grants and 3 option exercises.
The newest entry dates from 12 June 2018: a share grant of €127k, in PDL Biopharma, Inc. The latest purchase dates back some time: it was published 6,418 days ago, on 13 April 2009. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Paul W. Sandman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 54,348 shares@ US$2.7648.7% of flowCommon stockSEC:0000882104-18-000062:0
- 60,729 shares@ US$2.4727.6% of flowCommon stockSEC:0000882104-17-000067:0
- 71,023 shares@ US$3.5246.2% of flowCommon stockSEC:0000882104-16-000151:0
- 8,489 shares@ US$5.89Common StockSEC:0001209191-11-038544:0
- 10,000 shares@ US$7.38Common StockSEC:0001181431-09-019625:0Canonical exit: 7 Jul 2009 (T+90)
- 40,700 sharesCommon StockSEC:0001225208-08-005051:0
- 12,922 shares0Common StockSEC:0001225208-08-005051:1
- 45 shares0Common StockSEC:0001225208-07-010413:0
- 757 shares0Common StockSEC:0001225208-07-009838:0
- 8,000 sharesCommon StockSEC:0001225208-07-006541:0
- 3,340 shares@ US$15.48Common StockSEC:0001225208-07-006541:1
- 320,000 shares@ US$12.41Common StockSEC:0001225208-07-004382:0
- 700 shares@ US$15.83Common StockSEC:0001225208-07-004382:1
- 1,200 shares@ US$15.73Common StockSEC:0001225208-07-004382:2
- 2,500 shares@ US$15.98Common StockSEC:0001225208-07-004382:3
- 5,000 shares@ US$15.97Common StockSEC:0001225208-07-004382:4
- 5,000 shares@ US$15.90Common StockSEC:0001225208-07-004382:5
- 5,000 shares@ US$15.89Common StockSEC:0001225208-07-004382:6
- 5,000 shares@ US$15.68Common StockSEC:0001225208-07-004382:7
- 5,000 shares@ US$15.93Common StockSEC:0001225208-07-004382:8
- 5,800 shares@ US$15.82Common StockSEC:0001225208-07-004382:9
- 5,800 shares@ US$15.99Common StockSEC:0001225208-07-004382:10
- 6,700 shares@ US$16.00Common StockSEC:0001225208-07-004382:11
- 7,900 shares@ US$15.79Common StockSEC:0001225208-07-004382:12
- 8,400 shares@ US$15.69Common StockSEC:0001225208-07-004382:13
25 of 39 declarations
